Online inquiry

IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 2-Thio-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13926MR)

This product GTTS-WQ13926MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets INHBA gene. The antibody can be applied in Fibrodysplasia ossificans prograssiva (FOP) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_002192.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3624
UniProt ID P08476
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) (GTTS-WQ13926MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1549MR IVTScrip™ mRNA-Anti-BMP10&GDF2, ACE-041(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ACE-041
GTTS-WQ13854MR IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1193
GTTS-WQ14541MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SAR156597
GTTS-WQ5727MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ9000MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ3047MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ587MR IVTScrip™ mRNA-Anti-RTN4, 6A3-IgG4(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 6A3-IgG4
GTTS-WQ6970MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW